On November 11, Axsome Therapeutics saw an Intraday Rise of 4.28% in Regular Trading, trading at $149.84 per share, with turnover of $24.312 million.
The move aligns with continued market digestion of the company’s stronger-than-expected third-quarter results and improving visibility toward a potential profitability inflection.
In its latest reported quarter, Axsome Therapeutics posted EPS of -$0.25, materially better than market expectations of roughly -$0.56 to -$0.63, while revenue reached $259.7 million versus expectations of about $249 million. Auvelity net product sales were $207.6 million, reinforcing the view that continued commercial growth in the product could support profitability by 2027, although the ramp pace for the Alzheimer’s disease agitation indication still bears watching.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments